72.32 +0.11 (0.15%)
Pre-Market: 9:05AM EDT
|Bid||72.22 x 1800|
|Ask||72.95 x 1800|
|Day's Range||71.42 - 72.40|
|52 Week Range||52.83 - 72.89|
|Beta (3Y Monthly)||0.98|
|PE Ratio (TTM)||148.89|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.92 (2.67%)|
|1y Target Est||76.52|
NEW YORK, NY / ACCESSWIRE / October 19, 2018 / U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal ...
Jim Scholefield is leaving as Nike Inc.’s global CIO to join Merck & Co. as chief information and digital officer, effective Oct. 29. Mr. Scholefield will lead Merck’s information technology and digital strategy, the pharmaceutical company said in a statement Wednesday.
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.
Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer. The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent.
KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.
Merck (MRK), known as MSD outside the United States and Canada, today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct. 29, 2018. Scholefield will be responsible for leading Merck’s information technology and digital strategy and will be a member of the company’s Executive Committee.
Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
A $900 million disposal by Spain’s Iberdrola and a revenue warning from British American Tobacco are the corporate highlights in Europe on Tuesday.
Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.
Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.
A glimpse at the 30-stock blue-chip index will reveal that the recent meltdown is likely to be transitory and can provide a good entry point for investors.
New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.